Your shopping cart is currently empty

Inosine (NSC-20262), an endogenous purine nucleoside produced by the catabolism of adenosine, is an agonist of adenosine receptors A1R and A2AR. Inosine has anti-inflammatory, immunomodulatory, antinociceptive and neuroprotective effects.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 g | $29 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | In Stock | In Stock |
| Description | Inosine (NSC-20262), an endogenous purine nucleoside produced by the catabolism of adenosine, is an agonist of adenosine receptors A1R and A2AR. Inosine has anti-inflammatory, immunomodulatory, antinociceptive and neuroprotective effects. |
| Targets&IC50 | PvENT1:3.8 μM |
| In vitro | METHODS: Rat C6, DU-145, HaCaT, L6, and MCF7 cells were treated with Inosine (0-250 μM) for 48 hours, and MTT assay was used to detect the inhibition of cell growth. RESULTS: Inosine did not inhibit the growth of C6, DU-145, HaCaT, L6 and MCF7 cells at 250 μM. [1] |
| In vivo | METHODS: To study the analgesic effect of Inosine, Inosine (1 mg/kg, 10 mg/kg, and 100 mg/kg) was injected intraperitoneally to mice 20 min before formalin treatment. RESULTS: Inosine reduced formalin-induced leg withdrawal. [2] |
| Synonyms | NSC 20262, INO 495 |
| Molecular Weight | 268.23 |
| Formula | C10H12N4O5 |
| Cas No. | 58-63-9 |
| Smiles | O[C@H]1[C@H](N2C3=C(N=C2)C(=O)N=CN3)O[C@H](CO)[C@H]1O |
| Relative Density. | 2.08 g/cm3 |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: < 1 mg/mL (insoluble or slightly soluble) DMSO: 245 mg/mL (913.4 mM), Sonication is recommended. H2O: 43 mg/mL (160.31 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (18.64 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.